Parallel Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Parallel Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-200	Closed	-$4K	–	3420
2021 Q3	$4K	Sell	200 -38	-16%	-$1.05K	﹤0.01%	2529
2021 Q2	$9K	Buy	238 +38	+19%	+$1.17K	﹤0.01%	2081
2021 Q1	$5K	Hold	200	–	–	﹤0.01%	2230
2020 Q4	$4K	Hold	200	–	–	﹤0.01%	2162
2020 Q3	$4K	Hold	200	–	–	﹤0.01%	2154
2020 Q2	$5K	Buy	+200	New	+$4.31K	﹤0.01%	1988
2018 Q4	–	Sell	-2,000	Closed	-$31K	–	2359
2018 Q3	$31K	Buy	+2,000	New	+$29.1K	﹤0.01%	991

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Parallel Advisors's DRNA Position: Q4 2021 in Review

Parallel Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 200 shares — an estimated $4K sold.

Parallel Advisors first reported a position in DRNA in Q3 2018 and held it in 7 quarters. The position peaked at $31K in Q3 2018. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Parallel Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Parallel Advisors sold 200 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $4K.
Parallel Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2018 and held it in 7 quarters.
Parallel Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $31K in Q3 2018.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Parallel Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.